The Propel Mini Sinus Implant: A Breakthrough in Chronic Sinusitis Treatment with Nomisma’s PLGA

Intranasal Implant Releasing Controlled Cortisone: Propel Sinus Implant

The Propel Mini Sinus Implant: A Breakthrough in Chronic Sinusitis Treatment with Nomisma’s PLGA

The Propel mini sinus implant has revolutionized the treatment of chronic sinusitis, providing a cutting-edge solution that combines effective drug delivery with advanced biodegradable polymer technology. This FDA-approved device, developed by Intersect ENT, utilizes mometasone furoate (370 micrograms) to deliver localized anti-inflammatory treatment over a month. At the heart of this innovation is PLGA (poly(lactic-co-glycolic acid)), a biopolymer known for its versatile and customizable properties.

PLGA in the Propel Mini Sinus Implant

Nomisma Healthcare, a leading manufacturer of biopolymers, supplies high-quality PLGA for medical applications like the Propel mini implant. The specific PLGA used in this device is meticulously engineered to ensure precise drug release, biocompatibility, and degradation characteristics. Here are the critical specifications of the polymer:

  1. Composition Ratio (LA:GA): The PLGA in the Propel mini implant uses a 50:50 ratio of lactic acid (LA) to glycolic acid (GA), optimized for controlled degradation and drug release.
  2. End-Termination: The polymer is acid-terminated, enhancing its degradation properties and ensuring compatibility with the drug delivery system.
  3. Molecular Weight (MW): The PLGA has a molecular weight of 12,000 Da, balancing mechanical strength with a predictable degradation profile.
  4. Intrinsic Viscosity (IV): The intrinsic viscosity of the polymer is aligned with its molecular weight and drug release performance, ensuring efficient functionality.
  5. Degradation Rate: The polymer degrades over 4-6 weeks, aligning perfectly with the therapeutic duration of mometasone furoate.

The Role of Nomisma’s PLGA

Nomisma’s PLGA stands out due to its exceptional purity, customizable properties, and proven efficacy in drug delivery systems. Our stringent quality control processes ensure consistent polymer characteristics, enabling innovative medical solutions like the Propel mini implant. By leveraging Nomisma’s expertise, Intersect ENT has been able to create a device that significantly improves patient outcomes in chronic sinusitis treatment.

Advantages of PLGA in Sinus Implants

  • Localized Drug Delivery: PLGA enables controlled, localized delivery of mometasone furoate, reducing systemic side effects.
  • Biocompatibility: PLGA is FDA-approved and demonstrates excellent compatibility with human tissues.
  • Predictable Degradation: The polymer degrades into lactic acid and glycolic acid, which are naturally metabolized by the body.
  • Customizability: Properties such as LA:GA ratio, molecular weight, and end-group modification can be tailored for specific medical needs.

Conclusion

The Propel mini sinus implant exemplifies the transformative potential of PLGA in medical devices. Nomisma Healthcare is proud to be at the forefront of this innovation, supplying the high-quality PLGA that powers such breakthroughs. By partnering with Nomisma, healthcare innovators can continue to push the boundaries of patient care with reliable, customizable biopolymers.

Reference: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0d775ef5-ee26-49f3-ac77-cee25cdd0c0a

For detailed studies and access to the referenced research papers, contact us directly. Let Nomisma’s expertise elevate your medical innovations.